SLCO1B3-SLCO1B7

Across TCGA pan-cancer cohorts, SLCO1B3-SLCO1B7 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SLCO1B3-SLCO1B7 data layer compared with 17 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher SLCO1B3-SLCO1B7 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SLCO1B3-SLCO1B7 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

ACC, ESCA, and UCEC are the cancer types where SLCO1B3-SLCO1B7 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	OS	Median	All	0.145	0.888	<.001	45	view →
ESCA	OS	Median	II,III,IV	0.108	0.703	<.001	33	view →
UCEC	DFS	Median	All	0.969	0.829	.031	12	view →
BLCA	DFS	Median	III,IV	0.245	0.577	.014	6	view →
SKCM	OS	Median	II,III,IV	0.905	0.710	.016	4	view →
LUSC	OS	Median	All	0.427	0.734	.034	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SLCO1B3-SLCO1B7–ACC (OS)

Open the ACC breakdown →